Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CANbridge brings in $25mm through Series B round

Executive Summary

CANbridge Life Sciences Ltd. (developing oncology drugs, diagnostics, and devices for the Chinese and Northern Asian markets) raised $25mm through its Series B round to Lapam Capital (lead), Qiming Venture Partners, Yuanming Capital, Yanyuang Capital, Biossom Investment Management, and Wuxi AppTec. Money will support development of immunotherapy candidates CAN008 (Phase I/II for glioblastoma multiforme) and CAN017 (completed Phase I) for esophageal squamous cell cancer.
Deal Industry
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies